BioSight Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Carmiel Israel (2000)

Organization Overview

First Clinical Trial
2015
NCT02544438
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioSight Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: BioSight Ltd. (0) Acquired (1)

adxs11-001 (8 trials)

Drugs in Phase 2 Trials (9)

Key: BioSight Ltd. (2) Acquired (7)

adxs31-142 (1 trial)

adxs31-164 (1 trial)

adxs-503 (1 trial)

astarabine (1 trial)

attenuated live listeria encoding hpv 16 e7 vaccine (1 trial)

bst-236 (2 trials)

durvalumab (imfinzi) (1 trial)

pembrolizumab (keytruda) (2 trials)

pemetrexed (alimta) (1 trial)

Drugs in Phase 1 Trials (1)

Key: BioSight Ltd. (0) Acquired (1)

adxs-neo (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 11